Dr Weber discusses the FDA approval of adjuvant nivolumab for patients with completely resected stage IIB/C melanoma, key efficacy data from the CheckMate76K trial, and potential future directions for PD-1 inhibitor–based combinations in the melanoma treatment paradigm.
Publications
FDA Grants Fast Track Designation to LBS-007 in AML
LBS-007, a novel targeted therapy, has received FDA fast track designation for the treatment of acute myeloid leukemia.
FDA Clears IND for Tumor Infiltrating Lymphocyte Therapy
A phase 1/2 study of KSQ-001EX will commence at MD Anderson Cancer Center following this investigational new drug approval from the FDA.
FDA Approves Nivolumab for Completely Resected Stage IIB/C Melanoma
Approval is based on data from Bristol Myers Squibb’s CheckMate – 76K trial.